Your browser doesn't support javascript.
Autoantibodies against type I IFNs in patients with life-threatening COVID-19.
Bastard, Paul; Rosen, Lindsey B; Zhang, Qian; Michailidis, Eleftherios; Hoffmann, Hans-Heinrich; Zhang, Yu; Dorgham, Karim; Philippot, Quentin; Rosain, Jérémie; Béziat, Vivien; Manry, Jérémy; Shaw, Elana; Haljasmägi, Liis; Peterson, Pärt; Lorenzo, Lazaro; Bizien, Lucy; Trouillet-Assant, Sophie; Dobbs, Kerry; de Jesus, Adriana Almeida; Belot, Alexandre; Kallaste, Anne; Catherinot, Emilie; Tandjaoui-Lambiotte, Yacine; Le Pen, Jeremie; Kerner, Gaspard; Bigio, Benedetta; Seeleuthner, Yoann; Yang, Rui; Bolze, Alexandre; Spaan, András N; Delmonte, Ottavia M; Abers, Michael S; Aiuti, Alessandro; Casari, Giorgio; Lampasona, Vito; Piemonti, Lorenzo; Ciceri, Fabio; Bilguvar, Kaya; Lifton, Richard P; Vasse, Marc; Smadja, David M; Migaud, Mélanie; Hadjadj, Jérome; Terrier, Benjamin; Duffy, Darragh; Quintana-Murci, Lluis; van de Beek, Diederik; Roussel, Lucie; Vinh, Donald C; Tangye, Stuart G.
  • Bastard P; Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM U1163, Necker Hospital for Sick Children, Paris, France. jean-laurent.casanova@rockefeller.edu paul.bastard@institutimagine.org.
  • Rosen LB; University of Paris, Imagine Institute, Paris, France.
  • Zhang Q; St. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller University, New York, NY, USA.
  • Michailidis E; Laboratory of Clinical Immunology and Microbiology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA.
  • Hoffmann HH; St. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller University, New York, NY, USA.
  • Zhang Y; Laboratory of Virology and Infectious Disease, The Rockefeller University, New York, NY, USA.
  • Dorgham K; Laboratory of Virology and Infectious Disease, The Rockefeller University, New York, NY, USA.
  • Philippot Q; Laboratory of Clinical Immunology and Microbiology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA.
  • Rosain J; Sorbonne Université, INSERM, Centre d'Immunologie et des Maladies Infectieuses, (CIMI-Paris), Paris, France.
  • Béziat V; Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM U1163, Necker Hospital for Sick Children, Paris, France.
  • Manry J; University of Paris, Imagine Institute, Paris, France.
  • Shaw E; Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM U1163, Necker Hospital for Sick Children, Paris, France.
  • Haljasmägi L; University of Paris, Imagine Institute, Paris, France.
  • Peterson P; Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM U1163, Necker Hospital for Sick Children, Paris, France.
  • Lorenzo L; University of Paris, Imagine Institute, Paris, France.
  • Bizien L; St. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller University, New York, NY, USA.
  • Trouillet-Assant S; Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM U1163, Necker Hospital for Sick Children, Paris, France.
  • Dobbs K; University of Paris, Imagine Institute, Paris, France.
  • de Jesus AA; Laboratory of Clinical Immunology and Microbiology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA.
  • Belot A; Institute of Biomedicine and Translational Medicine, University of Tartu, Tartu, Estonia.
  • Kallaste A; Institute of Biomedicine and Translational Medicine, University of Tartu, Tartu, Estonia.
  • Catherinot E; Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM U1163, Necker Hospital for Sick Children, Paris, France.
  • Tandjaoui-Lambiotte Y; University of Paris, Imagine Institute, Paris, France.
  • Le Pen J; Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM U1163, Necker Hospital for Sick Children, Paris, France.
  • Kerner G; University of Paris, Imagine Institute, Paris, France.
  • Bigio B; Hospices Civils de Lyon, Lyon Sud Hospital, Pierre-Bénite, France.
  • Seeleuthner Y; International Center of Research in Infectiology, Lyon University, INSERM U1111, CNRS UMR 5308, ENS, UCBL, Lyon, France.
  • Yang R; Laboratory of Clinical Immunology and Microbiology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA.
  • Bolze A; Laboratory of Clinical Immunology and Microbiology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA.
  • Spaan AN; International Center of Research in Infectiology, Lyon University, INSERM U1111, CNRS UMR 5308, ENS, UCBL, Lyon, France.
  • Delmonte OM; National Referee Centre for Rheumatic and AutoImmune and Systemic Diseases in Children (RAISE), Lyon, France.
  • Abers MS; Lyon Immunopathology Federation (LIFE), Hospices Civils de Lyon, Lyon, France.
  • Aiuti A; Internal Medicine Clinic, Tartu University Hospital, Tartu, Estonia.
  • Casari G; Pneumology Department, Foch Hospital, Suresne, France.
  • Lampasona V; Avicenne Hospital, Assistance Publique Hôpitaux de Paris (AP-HP), Bobigny, INSERM U1272 Hypoxia and Lung, Bobigny, France.
  • Piemonti L; Laboratory of Virology and Infectious Disease, The Rockefeller University, New York, NY, USA.
  • Ciceri F; Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM U1163, Necker Hospital for Sick Children, Paris, France.
  • Bilguvar K; University of Paris, Imagine Institute, Paris, France.
  • Lifton RP; St. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller University, New York, NY, USA.
  • Vasse M; Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM U1163, Necker Hospital for Sick Children, Paris, France.
  • Smadja DM; University of Paris, Imagine Institute, Paris, France.
  • Migaud M; St. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller University, New York, NY, USA.
  • Hadjadj J; Helix, San Mateo, CA, USA.
  • Terrier B; St. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller University, New York, NY, USA.
  • Duffy D; Department of Medical Microbiology, University Medical Center Utrecht, Utrecht, Netherlands.
  • Quintana-Murci L; Laboratory of Clinical Immunology and Microbiology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA.
  • van de Beek D; Laboratory of Clinical Immunology and Microbiology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA.
  • Roussel L; IRCCS San Raffaele Hospital and Vita-Salute San Raffaele University, Milan, Italy.
  • Vinh DC; IRCCS San Raffaele Hospital and Vita-Salute San Raffaele University, Milan, Italy.
  • Tangye SG; IRCCS San Raffaele Hospital and Vita-Salute San Raffaele University, Milan, Italy.
Science ; 370(6515)2020 10 23.
Article in English | MEDLINE | ID: covidwho-889832
ABSTRACT
Interindividual clinical variability in the course of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is vast. We report that at least 101 of 987 patients with life-threatening coronavirus disease 2019 (COVID-19) pneumonia had neutralizing immunoglobulin G (IgG) autoantibodies (auto-Abs) against interferon-ω (IFN-ω) (13 patients), against the 13 types of IFN-α (36), or against both (52) at the onset of critical disease; a few also had auto-Abs against the other three type I IFNs. The auto-Abs neutralize the ability of the corresponding type I IFNs to block SARS-CoV-2 infection in vitro. These auto-Abs were not found in 663 individuals with asymptomatic or mild SARS-CoV-2 infection and were present in only 4 of 1227 healthy individuals. Patients with auto-Abs were aged 25 to 87 years and 95 of the 101 were men. A B cell autoimmune phenocopy of inborn errors of type I IFN immunity accounts for life-threatening COVID-19 pneumonia in at least 2.6% of women and 12.5% of men.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Autoantibodies / Interferon Type I / Coronavirus Infections / Interferon alpha-2 Type of study: Observational study / Prognostic study Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: English Year: 2020 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Autoantibodies / Interferon Type I / Coronavirus Infections / Interferon alpha-2 Type of study: Observational study / Prognostic study Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: English Year: 2020 Document Type: Article